Edition:
India

Fate Therapeutics Inc (FATE.OQ)

FATE.OQ on NASDAQ Stock Exchange Global Market

22.24USD
9:36pm IST
Change (% chg)

$-0.22 (-0.98%)
Prev Close
$22.46
Open
$22.39
Day's High
$22.59
Day's Low
$21.88
Volume
40,412
Avg. Vol
234,747
52-wk High
$22.75
52-wk Low
$8.64

Latest Key Developments (Source: Significant Developments)

Fate Therapeutics Reports Fourth Quarter And Full Year 2018 Financial Results
Wednesday, 6 Mar 2019 

March 5 (Reuters) - Fate Therapeutics Inc ::FATE THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND HIGHLIGHTS OPERATIONAL PROGRESS.Q4 REVENUE $1.7 MILLION VERSUS $1.0 MILLION.Q4 REVENUE ESTIMATE $2.9 MILLION -- REFINITIV IBES DATA.QTRLY NET LOSS PER COMMON SHARE $0.25.Q4 EARNINGS PER SHARE VIEW $-0.24 -- REFINITIV IBES DATA.  Full Article

Fate Therapeutics Says FDA Clears IND Application For Cell Therapy Derived From An Engineered Pluripotent Stem Cell
Wednesday, 6 Feb 2019 

Feb 6 (Reuters) - Fate Therapeutics Inc ::FATE THERAPEUTICS ANNOUNCES FDA CLEARANCE OF IND APPLICATION FOR WORLD’S FIRST CELL THERAPY DERIVED FROM AN ENGINEERED PLURIPOTENT STEM CELL.FATE THERAPEUTICS INC - FT516 OFF--SHELF NK CELL CANCER IMMUNOTHERAPY CLEARED FOR CLINICAL INVESTIGATION BY FDA.FATE THERAPEUTICS INC - FDA HAS ALLOWED ITS INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR FT516.FATE THERAPEUTICS INC - COMPANY INTENDS TO INITIATE CLINICAL TESTING OF FT516 IN PATIENTS WITH CERTAIN RELAPSED/REFRACTORY HEMATOLOGIC MALIGNANCIES.  Full Article

Fate Therapeutics Says NK100 Shows Clinical Benefit in Treating Advanced Hematologic Malignancies, Solid Tumors
Monday, 12 Nov 2018 

Nov 12 (Reuters) - Fate Therapeutics Inc ::FATE THERAPEUTICS ANNOUNCES ENCOURAGING DOSE-ESCALATION CLINICAL DATA OF FATE-NK100 AND PROVIDES REGULATORY UPDATE ON LANDMARK IND APPLICATION FOR FT500.NK100 SHOWS CLINICAL BENEFIT IN TREATING ADVANCED HEMATOLOGIC MALIGNANCIES AND SOLID TUMORS.SUBMITTED DATA TO FDA DEMONSTRATING FT500 MASTER IPSC BANK IS FREE OF ADVENTITIOUS AGENTS.  Full Article

Fate Therapeutics Prices Public Offering Of 9.26 Mln Common Shares At $13.50/Share
Friday, 21 Sep 2018 

Sept 20 (Reuters) - Fate Therapeutics Inc ::FATE THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 9.26 MILLION COMMON SHARES PRICED AT $13.50PER SHARE.  Full Article

Fate Therapeutics Announces Proposed Public Offering Of Common Stock
Friday, 21 Sep 2018 

Sept 20 (Reuters) - Fate Therapeutics Inc ::FATE THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.FATE THERAPEUTICS - INTENDS TO USE NET PROCEEDS FROM OFFERING TO FUND CLINICAL TRIALS AND NONCLINICAL STUDIES, AMONG OTHERS.  Full Article

Fate Therapeutics Reports Q2 Loss Per Share Of $0.37
Tuesday, 7 Aug 2018 

Aug 6 (Reuters) - Fate Therapeutics Inc ::FATE THERAPEUTICS REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND HIGHLIGHTS OPERATIONAL PROGRESS.Q2 REVENUE $1.0 MILLION VERSUS I/B/E/S VIEW $1.2 MILLION.QTRLY NET LOSS PER COMMON SHARE, BASIC AND DILUTED $0.37.  Full Article

Redmile Group LLC Reports 12.6 Pct Stake In Fate Therapeutics As Of July 31
Thursday, 2 Aug 2018 

Aug 2 (Reuters) - Redmile Group LLC: :REDMILE GROUP LLC REPORTS 12.6 PERCENT STAKE IN FATE THERAPEUTICS AS OF JULY 31 - SEC FILING.REDMILE GROUP - ON JULY 31, FATE BOARD APPOINTED REDMILE'S MICHAEL S. LEE TO SERVE AS DIRECTOR UNTIL FATE'S 2021 ANNUAL MEET.REDMILE GROUP - ACQUIRED FATE STOCK FOR INVESTMENT PURPOSE.  Full Article

Fate Therapeutics Announces Pricing Of Public Offering Of Common Stock
Wednesday, 13 Dec 2017 

Dec 13 (Reuters) - Fate Therapeutics Inc ::FATE THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 9.53 MILLION COMMON SHARES PRICED AT $4.20PER SHARE.  Full Article